乳酸片球菌ZJUIDS17在制备防治肝细胞癌的药物中的应用
The preparation of drugs for the prevention and treatment of hepatocellular carcinoma using Pediococcus lactis ZJUIDS17 solves the problem of the lack of effective prevention and treatment of hepatocellular carcinoma in the existing technology, and achieves the effect of significantly reducing liver tumor burden and enhancing intestinal barrier function, providing a safe and effective prevention and treatment method.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- ZHEJIANG UNIV
- Filing Date
- 2026-03-30
- Publication Date
- 2026-07-17
AI Technical Summary
Current technologies lack effective, low-toxicity methods to prevent and treat hepatocellular carcinoma. Traditional therapies such as surgical resection, chemotherapy, and targeted drugs have limitations and side effects. Furthermore, existing research on lactic acid bacteria mainly focuses on benign liver damage, while hepatocellular carcinoma is a malignant tumor, requiring new treatment strategies.
A drug for the prevention and treatment of hepatocellular carcinoma was prepared using Pediococcus lactis ZJUIDS17. The drug's efficacy was investigated by transfecting an orthotopic animal model of hepatocellular carcinoma under high pressure hydrodynamics. Live bacterial preparations, fermented milk products, and bacterial powder products were also developed to enhance intestinal barrier function, inhibit harmful bacteria, and have antioxidant capabilities.
It significantly reduces liver tumor burden, decreases tumor cell proliferation activity, enhances intestinal barrier function, alleviates liver damage, and provides a safe and effective means of preventing and treating hepatocellular carcinoma.
Smart Images
Figure CN122398868A_ABST